Tag: COVID-19

1. Children are most likely not the dominant drivers of COVID-19 transmissions, as their COVID test specimens were not as likely to grow in culture, had higher cycle thresholds in RT-PCR, and had lower viral concentrations, compared to adult specimens. Evidence Rating Level: 2 (Good) Although the pediatric population is a...
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant.  2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection. Evidence Rating Level: 1 (Excellent)      Study Rundown: With the emergence of COVID-19 variants, there is the...
1. Transfusion of high-titer convalescent antibody plasma was associated with a lower risk of death from coronavirus disease 2019 (COVID-19), compared to low-titered transfusions. 2. The mortality benefit of convalescent plasma antibodies was only observed in patients during earlier stages of the disease. Evidence Rating Level: 2 (Good) Study Rundown: During the...
1. COVID-19 infection during pregnancy was associated with consistent and substantial increases in severe maternal morbidity and mortality and neonatal complications compared to non-infected pregnancies, especially in symptomatic individuals presenting or those with co-morbidities. 2. Women with COVID-19 were at increased risk of severe pregnancy complications including pre-eclampsia/eclampsia, intensive care...
Infectivity of severe acute respiratory syndrome coronavirus 2 in children compared with adults 1. Children are most likely not the dominant drivers of COVID-19 transmissions, as their COVID test specimens were not as likely to grow in culture, had higher cycle thresholds in RT-PCR, and had lower viral concentrations, compared...
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant.  2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection. Evidence Rating Level: 1 (Excellent)      Study Rundown: With the emergence of COVID-19 variants, there...
1. Previous infection from SARS-CoV-2 was linked to an 84% lower incidence of reinfection. 2. Median interval between primary infection and reinfection of COVID-19 was greater than 200 days. Evidence Rating Level: 2 (Good) Study Rundown: While it has been suggested that a history of SARS-CoV-2 infection confers protection against subsequent infection,...
1. Patients from a large academic medical center with mild to moderate COVID-19 in receipt of the monoclonal antibody bamlanivimab had a lower 30-day rate of hospitalization. Evidence Level Rating: 2 (Good) Despite the extent to which SARS-CoV-2 has impacted the world and the delivery of medicine and pharmacotherapeutics, remdesivir, an RNA-dependent...
1. Hydroxychloroquine and lopinavir-ritonavir did not significantly decrease COVID-19–associated hospitalization or improve other secondary clinical outcomes. Evidence Rating Level: 1 (Excellent) Study Rundown: The COVID-19 pandemic, caused by the novel SARS-CoV-2 virus, has led to more than 146 million cases globally and more than 3.1 million deaths as of April 26,...
1. A nationwide mass vaccination setting was shown to be effective against coronavirus disease 2019 (COVID-19) related outcomes such as infections, hospitalization, and death after the second dose. 2. The study did not include participants affiliated with medical roles or those exposed to a medical environment such as health care...